---
created: 2025-04-13
updated: 2025-04-13T10:51
id: iblttpv]*2
specialty: nephro
specialty_id: 112
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::05-cardio::06-heart-failure::05-chronic-heart-failure
  - source/ak-step1-v11::
  - theme/b&b::19-renal::05-other::03-diuretics
  - source/ak-step1-v11::
  - theme/firstaid::14-renal::05-pharm::06-potassium-sparing-diuretics
  - source/ak-step1-v11::
  - source/ome-banner::clinical::01-cardiology::02-heart-failure
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::06-renal::05-potassium-sparing-diuretics
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::17-renal::aldosterone-receptor-blockers-(spironolactone,-eplerenone)
  - source/ak-step1-v11::
  - theme/sketchypharm::02-cardio-&-renal::02-diuretics::04-k+-sparing-diuretics
  - source/ak-step1-v11::
  - theme/uworld::100-999::600-699::686
  - source/ak-step1-v11::
  - theme/uworld::1000-9999::1000-1999::1565
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::renal::pharmacology"
type: flashcard
---

# Question
Do mineralocorticoid receptor antagonists (e.g. spironolactone, eplerenone) prolong life in heart failure?    **Yes**

---

# Answer
